Press Releases

TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000 (the “Offering”).

The Note matures on February 1, 2025 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $0.89, in the thirty-day period prior to the maturity of the Note.

Read more

TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide) has completed dosing of all scheduled volunteers and Metablok has met the primary endpoints of safety and tolerability. Metablok is the Company’s lead drug candidate for treating organ damage caused by inflammation.

Read more

TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today the U.S. Patent and Trademark Office (USPTO) has issued to Arch U.S. Patent number 10,493,127 titled, “Dipeptidase-1 Binding Compositions and Methods of Treatment”.

Read more

TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide), the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers.

Read more

TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr. Stephen Robbins and Dr. Paul Kubes at the University of Calgary, and their collaborators, have published a paper in the journal Cell describing a novel mechanism action for inflammation mediated organ injury involving the recruitment of white blood cells (neutrophils) from the bloodstream into injured or infected organ tissues.

Read more

TORONTO, June 19, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation.

Read more

TORONTO, March 19, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation.

Read more

TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance Program (“NRC-IRAP”) has approved funding totaling $200,000 for Arch scientists to further develop the Metablok (LSALT peptide) program. Metablok is the Company’s lead drug candidate for treating acute kidney injury and other organs damaged by inflammation.

Read more

TORONTO, Jan. 29, 2019 — Arch Biopartners Inc.,
PRESS RELEASE
FOR IMMEDIATE DISTRIBUTION

TORONTO, Jan. 29, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on January 24, 2019 for gross proceeds of CAD $500,000 (the “Offering”).

The Note matures on January 24, 2022 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.27, in the thirty-day period prior to the maturity of the Note.

Read more

TORONTO, Jan. 24, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $500,000 (the “Offering”).

The Note matures on January 24, 2022 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.27, in the thirty-day period prior to the maturity of the Note.

Read more